Journal
ONCOTARGETS AND THERAPY
Volume 12, Issue -, Pages 4789-4794Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S210168
Keywords
SOX30; methylation; chronic myeloid leukemia; progression
Categories
Funding
- National Natural Science Foundation of China [81270630]
- Medical Innovation Team of Jiangsu Province [CXTDB2017002]
- 333 Project of Jiangsu Province [BRA2016131]
- Six Talent Peaks Project in Jiangsu Province [2015-WSN-115]
- Zhenjiang Clinical Research Center of Hematology [SS2018009]
- Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX18_2281, KYCX17_1821]
- Social Development Foundation of Zhenjiang [SH2017040, SH2018044]
- Clinical Medical Science Development Foundation of Jiangsu University [JLY20160011]
- Natural Science Foundation of Jiangsu Province for Youths [BK20180280]
- Scientific Research Foundation of Affiliated People's Hospital of Jiangsu University for Ph.D. [KFB201603]
Ask authors/readers for more resources
Background: Our previous study has reported that aberrant SOX30 methylation was associated with poor prognosis in AML, and it correlated with disease progression in MDS. Herein, we further determined SOX30 methylation and its clinical significance in the other myeloid malignance - chronic myeloid leukemia (CML). Methods: SOX30 methylation was examined by real-time quantitative methylation-specific PCR and bisulfite sequencing PCR, whereas SOX30 expression was detected by real-time quantitative PCR. Results: SOX30 methylation was identified in 11% (10/95) CML patients. SOX30 methylation was associated with lower hemoglobin and platelets (P=0.006 and 0.032, respectively). Importantly, significant differences were observed in the distributions of clinical stages and cytogenetics (P=0.006 and 0.002, respectively). The frequency of SOX30 methylation in chronic phase (CP) stage occurred with lowest frequency (4/74, 5%), higher in accelerated phase (AP) stage (1/7, 14%), and the highest in blast crisis (BC) stage (12/31, 39%). In addition, SOX30 methylated patients tended to have a higher level of BCR-ABL transcript than SOX30 non-methylated patients (P=0.063). In two paired CML patients, SOX30 methylation showed lower density in CP stage (19% and 17%, respectively), and was significantly increased in BC stage (89% and 69%, respectively) during disease progression. Additionally, SOX30 methylated CML patients presented a lower SOX30 transcript level than SOX30 non-methylated CML patients (P=0.046). Conclusion: Our study revealed that SOX30 methylation correlated with disease progression in chronic myeloid leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available